Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …

Simple Summary Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its
current applications include the first-line setting, second-line setting, as well as the adjuvant …

Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor initially approved for treatment
of EGFR-positive patients exhibiting a T790 M resistance mutation in the second line setting …

Resistance mechanisms to osimertinib and emerging therapeuti... : Current Opinion in
Oncology Resistance mechanisms to osimertinib and emerging therapeutic strategies in …

The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been …

Abstract Treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth
factor receptor (EGFR) activating mutation with EGFR-TKIs has achieved great success, yet …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …

The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

The emergence of acquired resistance against targeted drugs remains a major clinical
challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an …